-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] The pharmaceutical and biological industry can be said to be the key area of institutional resear.
Recently, Xintian Pharmaceutical, Jiudian Pharmaceutical, and Tuoxin Pharmaceutical have released investor relations activity record shee.
Just recently, another pharmaceutical company announced that the company has been intensively investigated by institutio.
This is an innovative pharmaceutical company dedicated to the development of Best-in-class and First-in-class drugs - Haichuang Pharmaceutic.
According to the Investor Relations Activity Record Form released by Haichuang Pharmaceutical on August 1, the company accepted a survey of 61 institutions on July 27, 202 The types of institutions are QFII, insurance companies, others, fund companies, securities companies, Sunshine Private Equi.
Judging from the main content of investor relations activities, in the question-and-answer session, the company's project development plans, clinical progress, market space after listing, overseas cooperation, and commercial sales have attracted much attention from institutio.
Haichuang Pharmaceutical is an international innovative drug company based on technology platforms such as deuterated technology and PROTAC targeted protein degradation, aiming to develop Best-in-class and First-in-class drugs with major clinical nee.
The company's main products are oncology and metabolic disease dru.
The company focuses on the field of tumor and metabolic diseases, focusing on building a deuterated drug research and development platform, a PROTAC targeted protein degradation technology platform, a targeted drug discovery and verification platform, and a lead compound optimization screening platform, forming strong research and development advantages and Rich technical reserv.
According to reports, the company began to deploy PROTAC technology in 201 As of August 31, 2021, the company has applied for 25 invention patents related to PROTAC technology, including 5 patents in China and 16 in the United States, Japan, Europe, Australia and other countri.
3 authoriz.
Among the blockbuster products, HP518, a new drug for the treatment of drug-resistant prostate cancer, was independently developed and successfully promoted to enter Phase I clinical trials in Australia, and achieved the first patient administration (FI.
It is the first oral AR PROTAC in China to enter the clinical sta.
Drugs under investigati.
Another PROTAC drug under investigation, HC-X029, can simultaneously degrade full-length AR and AR splicing mutants including AR-v7, and is expected to have the potential to solve the drug resistance problem of current clinical drugs and address unmet clinical nee.
Among the products with rapid research and development progress in the second half of the year, the progress of deenluamide (HC-1119) is worthy of attenti.
The product's second- and third-line treatment of metastatic castration-resistant prostate cancer has been reviewed by the Independent Data Monitoring Committee (IDMC) and determined that the trial has reached the pre-set primary endpoi.
The center submitted a pre-market communication application in China, and the drug for first-line treatment of metastatic castration-resistant prostate cancer has been approved by the FDA and NMPA in 2019 to enter a global multi-center clinical phase III trial, and relevant clinical trials are ongoi.
In addition, the monotherapy of HP501 for hyperuricemia/gout indications has completed Phase II clinical trials and is initiating Phase III clinical tria.
The PROTAC drug HP518, which acts on AR and treats drug-resistant prostate cancer, has launched a phase I clinical trial in Australia and is progressing smooth.
In terms of commercialization, the company stated that it is building a core marketing team with rich experience in clinical market launch and promotion, whose main functions include early promotion, market expansion and commercial activiti.
It is planned to introduce talents with rich professional knowledge and strong market development ability in the field of cancer, especially in the field of urological cancer, to be responsible for the development of products in various provinces and cities across the country and even the global mark.
Products are promoted in the form of exhibitions and academic activiti.
At present, since all the products under development of the company are in the research and development stage and have not yet been commercialized for production and sales, product sales revenue has not yet been realiz.
According to the first quarterly report of 2022, the net loss attributable to shareholders of the listed company during the period was 88998 million yuan; the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 93322 million yuan; the basic loss per share was 17 yuan per sha.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Recently, Xintian Pharmaceutical, Jiudian Pharmaceutical, and Tuoxin Pharmaceutical have released investor relations activity record shee.
Just recently, another pharmaceutical company announced that the company has been intensively investigated by institutio.
This is an innovative pharmaceutical company dedicated to the development of Best-in-class and First-in-class drugs - Haichuang Pharmaceutic.
According to the Investor Relations Activity Record Form released by Haichuang Pharmaceutical on August 1, the company accepted a survey of 61 institutions on July 27, 202 The types of institutions are QFII, insurance companies, others, fund companies, securities companies, Sunshine Private Equi.
Judging from the main content of investor relations activities, in the question-and-answer session, the company's project development plans, clinical progress, market space after listing, overseas cooperation, and commercial sales have attracted much attention from institutio.
Haichuang Pharmaceutical is an international innovative drug company based on technology platforms such as deuterated technology and PROTAC targeted protein degradation, aiming to develop Best-in-class and First-in-class drugs with major clinical nee.
The company's main products are oncology and metabolic disease dru.
The company focuses on the field of tumor and metabolic diseases, focusing on building a deuterated drug research and development platform, a PROTAC targeted protein degradation technology platform, a targeted drug discovery and verification platform, and a lead compound optimization screening platform, forming strong research and development advantages and Rich technical reserv.
According to reports, the company began to deploy PROTAC technology in 201 As of August 31, 2021, the company has applied for 25 invention patents related to PROTAC technology, including 5 patents in China and 16 in the United States, Japan, Europe, Australia and other countri.
3 authoriz.
Among the blockbuster products, HP518, a new drug for the treatment of drug-resistant prostate cancer, was independently developed and successfully promoted to enter Phase I clinical trials in Australia, and achieved the first patient administration (FI.
It is the first oral AR PROTAC in China to enter the clinical sta.
Drugs under investigati.
Another PROTAC drug under investigation, HC-X029, can simultaneously degrade full-length AR and AR splicing mutants including AR-v7, and is expected to have the potential to solve the drug resistance problem of current clinical drugs and address unmet clinical nee.
Among the products with rapid research and development progress in the second half of the year, the progress of deenluamide (HC-1119) is worthy of attenti.
The product's second- and third-line treatment of metastatic castration-resistant prostate cancer has been reviewed by the Independent Data Monitoring Committee (IDMC) and determined that the trial has reached the pre-set primary endpoi.
The center submitted a pre-market communication application in China, and the drug for first-line treatment of metastatic castration-resistant prostate cancer has been approved by the FDA and NMPA in 2019 to enter a global multi-center clinical phase III trial, and relevant clinical trials are ongoi.
In addition, the monotherapy of HP501 for hyperuricemia/gout indications has completed Phase II clinical trials and is initiating Phase III clinical tria.
The PROTAC drug HP518, which acts on AR and treats drug-resistant prostate cancer, has launched a phase I clinical trial in Australia and is progressing smooth.
In terms of commercialization, the company stated that it is building a core marketing team with rich experience in clinical market launch and promotion, whose main functions include early promotion, market expansion and commercial activiti.
It is planned to introduce talents with rich professional knowledge and strong market development ability in the field of cancer, especially in the field of urological cancer, to be responsible for the development of products in various provinces and cities across the country and even the global mark.
Products are promoted in the form of exhibitions and academic activiti.
At present, since all the products under development of the company are in the research and development stage and have not yet been commercialized for production and sales, product sales revenue has not yet been realiz.
According to the first quarterly report of 2022, the net loss attributable to shareholders of the listed company during the period was 88998 million yuan; the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 93322 million yuan; the basic loss per share was 17 yuan per sha.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
